List Criteria

    A2. Commits to comply with human rights standards in product development & marketing

     

    T1. Publishes its R&D costs.

     

    T2. Publishes its profit margin.

     

    T3. The company publishes the average and/or marginal costs of production.

     

    T4. Publishes its production capacity.

     

    T5. The company publishes the public subsidies it received during product development and/or testing

     

    T6. Publishes the text of licensing agreements.

     

    T7. Registers its clinical trials in public repositories.

     

    C1. The company commits to C-TAP or MPP

     

    C2. Commits to not enforcing the exclusive rights of Covid-19 related patents.

     

    C3. Supplies to, or signs agreements with, the vaccines or therapeutics pillar of the ACT Accelerator.

     

    E1. The company makes the active ingredient available on reasonable grounds. [ therapeutics only]

     

    E2. Commits to full technology transfer to other manufacturers.

     

    E3. Commits to non-profit or ‘fair’ pricing.

     

    E6. Agrees to waive exclusive rights in regulatory test data [where applicable].

     

    E4. Equitably distributes supplies globally. [vaccines only]

     

    E5. The company does not seek protection beyond the minimum criteria in TRIPS, or enforces TRIPS+ measures [where applicable]

     

    A1. Publishes a global access plan for its product.